JP2002544164A - ５−（２−クロロエチル）−４−メチルチアゾールエジシレート（クロメチアゾールエジシレート）の非経口処方物 - Google Patents
５−（２−クロロエチル）−４−メチルチアゾールエジシレート（クロメチアゾールエジシレート）の非経口処方物Info
- Publication number
- JP2002544164A JP2002544164A JP2000616779A JP2000616779A JP2002544164A JP 2002544164 A JP2002544164 A JP 2002544164A JP 2000616779 A JP2000616779 A JP 2000616779A JP 2000616779 A JP2000616779 A JP 2000616779A JP 2002544164 A JP2002544164 A JP 2002544164A
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- edisylate
- neurodegeneration
- sodium chloride
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940099950 clomethiazole edisylate Drugs 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims description 62
- 238000009472 formulation Methods 0.000 title claims description 60
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 title abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 59
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 48
- 239000011780 sodium chloride Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 230000004770 neurodegeneration Effects 0.000 claims description 16
- 208000006011 Stroke Diseases 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- 230000002378 acidificating effect Effects 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 201000006474 Brain Ischemia Diseases 0.000 claims description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
- 206010008118 cerebral infarction Diseases 0.000 claims description 5
- 230000007954 hypoxia Effects 0.000 claims description 5
- 208000020431 spinal cord injury Diseases 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 208000002381 Brain Hypoxia Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 5
- 206010021143 Hypoxia Diseases 0.000 claims 3
- 230000000845 anti-microbial effect Effects 0.000 abstract description 13
- 230000002906 microbiologic effect Effects 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- HEJVROKEIMJTIN-UHFFFAOYSA-N (2-butan-2-yl-4,6-dinitrophenyl) (2,4-dinitrophenyl) carbonate Chemical compound CCC(C)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HEJVROKEIMJTIN-UHFFFAOYSA-N 0.000 description 4
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 4
- 229960000673 dextrose monohydrate Drugs 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 239000007951 isotonicity adjuster Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- HXVHKHDEUMNKRY-UHFFFAOYSA-N 2-(2-chloroethyl)-4-methyl-1,3-thiazole Chemical compound CC1=CSC(CCCl)=N1 HXVHKHDEUMNKRY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9901658-6 | 1999-05-06 | ||
| SE9901658A SE9901658D0 (sv) | 1999-05-06 | 1999-05-06 | New formulation |
| PCT/SE2000/000876 WO2000067753A1 (fr) | 1999-05-06 | 2000-05-04 | Formulation parenterale de 5-(2-chloroethyle)-4-methylthiazole edisylate(clomethiazole edisylate) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002544164A true JP2002544164A (ja) | 2002-12-24 |
Family
ID=20415507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000616779A Pending JP2002544164A (ja) | 1999-05-06 | 2000-05-04 | ５−（２−クロロエチル）−４−メチルチアゾールエジシレート（クロメチアゾールエジシレート）の非経口処方物 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1178798A1 (fr) |
| JP (1) | JP2002544164A (fr) |
| AR (1) | AR023873A1 (fr) |
| AU (1) | AU4792200A (fr) |
| SE (1) | SE9901658D0 (fr) |
| TN (1) | TNSN00094A1 (fr) |
| WO (1) | WO2000067753A1 (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK733888A (da) * | 1988-01-12 | 1989-07-13 | Fujisawa Pharmaceutical Co | Stabiliseringsmiddel |
| IL91856A0 (en) * | 1988-10-11 | 1990-06-10 | Schiapparelli Salute Spa | Pharmaceutical compositions comprising calcitonin for intranasal administration and a spray unit for the administration of the same |
| SE8900564D0 (sv) * | 1989-02-17 | 1989-02-17 | Astra Ab | Novel medicinal use |
| SE9002659D0 (sv) * | 1990-08-15 | 1990-08-15 | Astra Ab | New pharmaceutical formulations |
-
1999
- 1999-05-06 SE SE9901658A patent/SE9901658D0/xx unknown
-
2000
- 2000-05-03 TN TNTNSN00094A patent/TNSN00094A1/fr unknown
- 2000-05-04 EP EP00930026A patent/EP1178798A1/fr not_active Withdrawn
- 2000-05-04 JP JP2000616779A patent/JP2002544164A/ja active Pending
- 2000-05-04 WO PCT/SE2000/000876 patent/WO2000067753A1/fr not_active Application Discontinuation
- 2000-05-04 AU AU47922/00A patent/AU4792200A/en not_active Abandoned
- 2000-05-05 AR ARP000102193A patent/AR023873A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE9901658D0 (sv) | 1999-05-06 |
| AR023873A1 (es) | 2002-09-04 |
| EP1178798A1 (fr) | 2002-02-13 |
| WO2000067753A1 (fr) | 2000-11-16 |
| TNSN00094A1 (fr) | 2002-05-30 |
| AU4792200A (en) | 2000-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6548079B1 (en) | Moxifloxacin formulation containing common salt | |
| US10561607B2 (en) | Pharmaceutical compositions comprising gels and methods for fabricating thereof | |
| TWI544934B (zh) | 含有氟喹諾酮抗生素藥物之經改良藥學組成物 | |
| AU771027B2 (en) | Pharmaceutical solutions of levosimendan | |
| CA2867295A1 (fr) | Formulations de bendamustine | |
| TW200526235A (en) | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use | |
| JP2916340B2 (ja) | ナトリウムクロモグリケートの水性医薬組成物 | |
| JPH064534B2 (ja) | 長期間の疼痛緩和をもたらす配合剤 | |
| NZ548028A (en) | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same | |
| US20200155450A1 (en) | Pharmaceutical compositions comprising gels and methods for fabricating thereof | |
| CN105769756B (zh) | 一种富马酸西他沙星注射剂及其制备方法 | |
| JP2002544164A (ja) | ５−（２−クロロエチル）−４−メチルチアゾールエジシレート（クロメチアゾールエジシレート）の非経口処方物 | |
| EP3435976B1 (fr) | Compositions antibactériennes | |
| CN116847826A (zh) | 包含左氧氟沙星和酮咯酸的眼用组合物、其制备方法和用途 | |
| WO2014139677A1 (fr) | Préparation parentérale d'agent antibactérien à base de fluoroquinolone et procédé de préparation associé | |
| MXPA94003569A (en) | Stable quinolone and naphthyridine premix formulations |